The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Takami A, Kinugasa Y, Kamitani H, Nakamura K, Hirai M, Yanagihara K, Matsubara K, Kato M, Yamamoto K

Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure.

International heart journal. 2022;63(2):247-254

Morimoto T, Yamasaki K, Isoshima Y, Yatera K

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma.

Internal medicine (Tokyo, Japan). 2022;61(17):2697-2698

Brie V, Faure M, Garon J, Petit I, Gomez E, Knoepfli A, Decavele M, Petitpain N, Chabot F, Chaouat A

[Drug-induced interstitial pneumonitis due to avelumab: A case report].

Revue des maladies respiratoires. 2018;35(9):978-982